MX2022009943A - Vacunas intranasales de arnm. - Google Patents
Vacunas intranasales de arnm.Info
- Publication number
- MX2022009943A MX2022009943A MX2022009943A MX2022009943A MX2022009943A MX 2022009943 A MX2022009943 A MX 2022009943A MX 2022009943 A MX2022009943 A MX 2022009943A MX 2022009943 A MX2022009943 A MX 2022009943A MX 2022009943 A MX2022009943 A MX 2022009943A
- Authority
- MX
- Mexico
- Prior art keywords
- mrna
- intranasal
- molecules
- specifically
- antigen
- Prior art date
Links
- 108700021021 mRNA Vaccine Proteins 0.000 title abstract 2
- 229940126582 mRNA vaccine Drugs 0.000 title abstract 2
- 239000000427 antigen Substances 0.000 abstract 4
- 102000036639 antigens Human genes 0.000 abstract 4
- 108091007433 antigens Proteins 0.000 abstract 4
- 108020004999 messenger RNA Proteins 0.000 abstract 3
- 230000003308 immunostimulating effect Effects 0.000 abstract 2
- 230000001717 pathogenic effect Effects 0.000 abstract 2
- 229960005486 vaccine Drugs 0.000 abstract 2
- 108010029697 CD40 Ligand Proteins 0.000 abstract 1
- 102100032937 CD40 ligand Human genes 0.000 abstract 1
- 102100025221 CD70 antigen Human genes 0.000 abstract 1
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 abstract 1
- 210000000612 antigen-presenting cell Anatomy 0.000 abstract 1
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000008021 deposition Effects 0.000 abstract 1
- 230000002538 fungal effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001136—Cytokines
- A61K39/001138—Tumor necrosis factors [TNF] or CD70
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención se refiere en general a vacunas intranasales de ARNm, más en particular que comprenden una o más moléculas inmunoestimuladoras, uno o más antígenos patógenos y un sistema de administración diseñado específicamente. Específicamente, dichas moléculas inmunoestimuladoras y antígenos patógenos se proporcionan en forma de moléculas de ARNm que codifican para tales moléculas y antígenos; más en particular, moléculas de ARNm que codifican para CD40L, caTLR4 y/o CD70 en combinación con una o más moléculas de ARNm que codifican para un antígeno bacteriano, viral o fúngico. Dicho específicamente, el suministro es una mezcla de compuestos químicos que permiten la protección y el depósito de la vacuna y el direccionamiento a las células presentadoras de antígenos en la nariz. En particular, la presente invención es muy adecuada para el desarrollo de una vacuna de respuesta rápida en un contexto de brote epidémico.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20157300 | 2020-02-14 | ||
| PCT/EP2021/053633 WO2021160881A1 (en) | 2020-02-14 | 2021-02-15 | Intranasal mrna vaccines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022009943A true MX2022009943A (es) | 2022-10-18 |
Family
ID=69593570
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022009943A MX2022009943A (es) | 2020-02-14 | 2021-02-15 | Vacunas intranasales de arnm. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230071518A1 (es) |
| EP (1) | EP4103226A1 (es) |
| JP (1) | JP2023518340A (es) |
| KR (1) | KR20230004447A (es) |
| CN (1) | CN115443148A (es) |
| AU (1) | AU2021219304A1 (es) |
| BR (1) | BR112022015666A2 (es) |
| CA (1) | CA3170239A1 (es) |
| IL (1) | IL295507A (es) |
| MX (1) | MX2022009943A (es) |
| TW (1) | TW202144002A (es) |
| WO (1) | WO2021160881A1 (es) |
| ZA (1) | ZA202209779B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11576966B2 (en) | 2020-02-04 | 2023-02-14 | CureVac SE | Coronavirus vaccine |
| US11241493B2 (en) | 2020-02-04 | 2022-02-08 | Curevac Ag | Coronavirus vaccine |
| MX2023007574A (es) | 2020-12-22 | 2023-09-29 | CureVac SE | "vacuna de arn contra variantes de sars-cov-2. |
| WO2023037320A1 (en) * | 2021-09-10 | 2023-03-16 | Intron Biotechnology, Inc. | Mucosal messenger rna vaccine |
| WO2023108076A1 (en) * | 2021-12-08 | 2023-06-15 | Yale University | Surface conjugation to poly(amine-co-ester) nanoparticles for targeting to cells and tissues |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130108663A1 (en) * | 2007-09-14 | 2013-05-02 | Vrije Universiteit Brussel | Enhancing the t-cell stimulatory capacity of human antigen presenting cells in vitro and in vivo and their use in vaccination |
| DK3336192T3 (da) * | 2013-11-12 | 2022-03-14 | Univ Brussel Vrije | Rna-transskriptionsvektor og anvendelser deraf |
| EP3981437A1 (en) * | 2014-04-23 | 2022-04-13 | ModernaTX, Inc. | Nucleic acid vaccines |
| AU2017350488B2 (en) * | 2016-10-26 | 2022-06-23 | Acuitas Therapeutics Inc. | Lipid nanoparticle mRNA vaccines |
-
2021
- 2021-02-15 CN CN202180009112.1A patent/CN115443148A/zh active Pending
- 2021-02-15 US US17/799,118 patent/US20230071518A1/en active Pending
- 2021-02-15 JP JP2022548838A patent/JP2023518340A/ja active Pending
- 2021-02-15 AU AU2021219304A patent/AU2021219304A1/en active Pending
- 2021-02-15 EP EP21705192.9A patent/EP4103226A1/en active Pending
- 2021-02-15 BR BR112022015666A patent/BR112022015666A2/pt unknown
- 2021-02-15 IL IL295507A patent/IL295507A/en unknown
- 2021-02-15 CA CA3170239A patent/CA3170239A1/en active Pending
- 2021-02-15 WO PCT/EP2021/053633 patent/WO2021160881A1/en active Search and Examination
- 2021-02-15 KR KR1020227031704A patent/KR20230004447A/ko unknown
- 2021-02-15 MX MX2022009943A patent/MX2022009943A/es unknown
- 2021-02-17 TW TW110105299A patent/TW202144002A/zh unknown
-
2022
- 2022-09-01 ZA ZA2022/09779A patent/ZA202209779B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3170239A1 (en) | 2021-08-19 |
| WO2021160881A9 (en) | 2022-11-10 |
| CN115443148A (zh) | 2022-12-06 |
| US20230071518A1 (en) | 2023-03-09 |
| WO2021160881A1 (en) | 2021-08-19 |
| TW202144002A (zh) | 2021-12-01 |
| KR20230004447A (ko) | 2023-01-06 |
| AU2021219304A1 (en) | 2022-10-06 |
| JP2023518340A (ja) | 2023-05-01 |
| IL295507A (en) | 2022-10-01 |
| EP4103226A1 (en) | 2022-12-21 |
| ZA202209779B (en) | 2024-01-31 |
| BR112022015666A2 (pt) | 2022-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202209779B (en) | Intranasal mrna vaccines | |
| Krammer et al. | Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies | |
| Martinez-Gil et al. | A Sendai virus-derived RNA agonist of RIG-I as a virus vaccine adjuvant | |
| Rappazzo et al. | Recombinant M2e outer membrane vesicle vaccines protect against lethal influenza A challenge in BALB/c mice | |
| Kim et al. | Virus-like particles containing multiple M2 extracellular domains confer improved cross-protection against various subtypes of influenza virus | |
| Li et al. | Messenger RNA vaccine based on recombinant MS2 virus‐like particles against prostate cancer | |
| Torrieri-Dramard et al. | Intranasal DNA vaccination induces potent mucosal and systemic immune responses and cross-protective immunity against influenza viruses | |
| Kamlangdee et al. | Broad protection against avian influenza virus by using a modified vaccinia Ankara virus expressing a mosaic hemagglutinin gene | |
| Harding et al. | Rationally designed influenza virus vaccines that are antigenically stable during growth in eggs | |
| Grasso et al. | Successful therapeutic vaccination with integrase defective lentiviral vector expressing nononcogenic human papillomavirus E7 protein | |
| Becker et al. | Influenza vaccines: successes and continuing challenges | |
| WO2022221440A8 (en) | Influenza-coronavirus combination vaccines | |
| Huang et al. | Influenza A virus nucleoprotein derived from Escherichia coli or recombinant vaccinia (Tiantan) virus elicits robust cross-protection in mice | |
| MX357505B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| WO2022221335A8 (en) | Respiratory virus combination vaccines | |
| MX2013008836A (es) | Moleculas de acido nucleico que codifican novedosos antigenos de herpes, vacunas que las comprenden y metodos para su uso. | |
| Wang et al. | Robust immunity and heterologous protection against influenza in mice elicited by a novel recombinant NP-M2e fusion protein expressed in E. coli | |
| MX2021015465A (es) | Vacuna para fiebre porcina africana. | |
| Andersen et al. | A DNA vaccine that targets hemagglutinin to antigen-presenting cells protects mice against H7 influenza | |
| DOP2012000164A (es) | Polipeptido de fusion contra tumor inducido por virus eb y mutante de colicina ia | |
| Kamlangdee et al. | Mosaic H5 hemagglutinin provides broad humoral and cellular immune responses against influenza viruses | |
| Kim et al. | Complement C3 plays a key role in inducing humoral and cellular immune responses to influenza virus strain-specific hemagglutinin-based or cross-protective M2 extracellular domain-based vaccination | |
| AU2021238777A8 (en) | Modified mRNAs for vaccine development | |
| Chen et al. | Evaluation of three live attenuated H2 pandemic influenza vaccine candidates in mice and ferrets | |
| MX2021012984A (es) | Anticuerpos y metodos para el tratamiento de la infeccion por influenza a. |